Publikasi Scopus FKUI 2021 per tanggal 30 April 2021 (299 artikel)

Atmosudigdo I.S., Lim M.A., Radi B., Henrina J., Yonas E., Vania R., Pranata R.
57222578186;57216039756;6603494019;57218482646;57201987097;57208328436;57201973901;
Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression
2021
Clinical Medicine Insights: Endocrinology and Diabetes
14
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Balaraja General Hospital, Tangerang, Indonesia; Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Division of Plastic, Reconstructive and Aesthetic, Department of Surgery, Faculty of Medicine, Sanglah General Hospital, Udayana University, Bali, Indonesia
Atmosudigdo, I.S., Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Lim, M.A., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Radi, B., Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Henrina, J., Balaraja General Hospital, Tangerang, Indonesia; Yonas, E., Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia; Vania, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia, Division of Plastic, Reconstructive and Aesthetic, Department of Surgery, Faculty of Medicine, Sanglah General Hospital, Udayana University, Bali, Indonesia; Pranata, R., Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia
Objective: This systematic review and meta-analysis aimed to evaluate whether dyslipidemia affects the mortality and severity of COVID-19, we also aimed to evaluate whether other comorbidities influence the association. Methods: A systematic literature search using PubMed, Embase, and EuropePMC was performed on 8 October 2020. This study’s main outcome is a poor composite outcome, comprising of mortality and severe COVID-19. Results: There were 9 studies with 3663 patients. The prevalence of dyslipidemia in this pooled analysis was 18% (4%-32%). Dyslipidemia was associated with increased composite poor outcome (RR 1.39 [1.02, 1.88], P =.010; I2: 56.7%, P =.018). Subgroup analysis showed that dyslipidemia was associated with severe COVID-19 (RR 1.39 [1.03, 1.87], P =.008; I2: 57.4%, P =.029). Meta-regression showed that the association between dyslipidemia and poor outcome varies by age (coefficient: −0.04, P =.033), male gender (coefficient: −0.03, P =.042), and hypertension (coefficient: −0.02, P =.033), but not diabetes (coefficient: −0.24, P =.135) and cardiovascular diseases (coefficient: −0.01, P =.506). Inverted funnel-plot was relatively symmetrical. Egger’s test indicates that the pooled analysis was not statistically significant for small-study effects (P =.206). Conclusion: Dyslipidemia potentially increases mortality and severity of COVID-19. The association was stronger in patients with older age, male, and hypertension. PROSPERO Registration Number: CRD42020213491 © The Author(s) 2021.
coronavirus; COVID-19; dyslipidemia; hyperlipidemia; prognosis
SAGE Publications Ltd
11795514
Article
Q2
657
7465